Competitive Intelligence in Pharma: How Companies Are Using Modern M&CI Platforms

With drug development costs rising, generic and biosimilar production increasing due to patent expiries, governments putting increasing pressure on regulated prices, and the rise of AI technologies, the pharma industry is becoming more competitive than ever. Pharma companies need to stay on top of commercial strategies, regulatory updates, R&D cycles, competitor pipelines, clinical trial developments, market shifts, pricing trends, and emerging therapies. Moreover, being defined by a high-stakes environment, one misstep could lead to years of lost development cycles and billions of dollars in losses. To combat this, structured market and competitive intelligence (M&CI) in pharma becomes imperative.

A pharma market and competitive intelligence (M&CI) program enables teams to navigate the current business landscape with confidence and predict what could come next, so they can make strategic decisions in R&D strategy, portfolio decisions, commercial development, BD&L, and more.

In this blog, we will explore how pharma market and competitive intelligence unlocks actionable and forward-looking insights, use cases of pharma competitive intelligence, and how AI transforms intelligence workflows, enabling pharma teams to move from reactive monitoring to proactive, data-driven decision-making.

What is market and competitive Intelligence in Pharma

Market and competitive intelligence in pharma is a continuous process of automatically sourcing, validating, analyzing, and distributing insights regarding competitors’ pipelines, clinical trials, regulatory activity, deals, commercial moves, and more to drive strategic decisions.

In pharma, strategy rarely depends only on competitor activity. Market shifts such as regulatory approvals, customer behavior, and pricing and reimbursement dynamics significantly influence whether a product will exist, get approved, or become needed in the treatment.

A comprehensive pharma intelligence program offers strategic value by focusing on both competitor moves and market developments. It is important to prioritize pharma market and competitive intelligence platforms that continuously monitor signals across sources like clinical trials, regulatory filings, scientific publications, patents, company announcements, and industry news, turn those signals into intelligence, and finally deliver it to the stakeholders in a timely and as per their unique strategic requirements.

Since pharma industry development cycles can take over a decade, R&D development starts long before a product reaches the market, with years of research, clinical trials, regulatory reviews, and commercialization planning involved, so a pharma intelligence tools must not only surface current developments, but also provides historical data so that teams can understand how the market and competitive landscape has evolved over time, and along with this, offers predictive insights that help you anticipate competitor moves, market shifts, and emerging opportunities and threats to stay future-ready.

Challenges that hinder strategic decisions for pharma intelligence teams

Pharma competitive intelligence teams face multiple challenges, such as:

Pharma intelligence remains scattered across disconnected sources

Most pharmaceutical competitive intelligence programs are solely built on specialized databases, including clinical trial databases, drug pipeline databases, and pharma intelligence databases. These databases may offer depth of information but don’t offer a breadth of targeted source coverage based on your unique requirements, such as region, product, themes, disease areas, therapeutic areas, competitors, and specific sources. They also don’t integrate with internal datasets to contextualize insights, such as clinical trial metrics, real-world patient data, or CRM notes. It also requires extra manual effort from analysts to validate and clean this data.

Intelligence without strategic context limits decision value

When you only rely on specialized datasets for pharma intelligence, your closest competitors also get the same datasets and act on the same intelligence. The unique signals that matter to your strategy are usually different from your competitors’. When intelligence isn’t filtered through your strategic priorities, core strengths, and weaknesses, you miss important signals, such as emerging companies and technologies that threaten your portfolio, or regulatory and competitive shifts that uniquely affect you.

Too much information makes critical signals harder to spot

As of 2026, precisely 598,690 studies are published on ClinicalTrials.gov. Add regulatory databases, patent filings, medical literature, conference proceedings, company websites, earnings calls, licensing activity, M&A, KOL activity, payer developments, and internal research, and the pharma intelligence environment becomes significantly more fragmented, causing blind spots and missed opportunities. Analyzing, deduplicating, and contextualizing this overwhelming data becomes extremely challenging without a purpose-built pharma competitive intelligence platform.

Weak dissemination creates a last-mile intelligence gap

Most M&CI platforms focus on data gathering and analysis, but the dissemination process often remains weak. There’s no consistent format, cadence, and traceability to ensure intelligence is distributed and utilized effectively internally, leading to gaps. Moreover, most specialized datasets rarely offer role-specific, highly configurable intelligence dissemination capabilities, which is a crucial process of any intelligence program or platform.

Horizontal AI lacks the context required for pharma market and competitive intelligence

Generic AI tools like ChatGPT, Claude, or Gemini are not configured to serve pharma intelligence workflows. These tools act as query-based models and black boxes, as they are built to predict the most mathematically probable next word based on patterns, rather than checking reality – resulting in unverified insights. In the pharma industry, where a wrong move can significantly impact years of pipeline developments and portfolios, trusting AI models that don’t understand your strategic context and proprietary intelligence is a high-risk approach.

Use Cases of Market and Competitive Intelligence in Pharma

1. BD&L: Identify opportunities and understand where competitors are placing their bets

Market and competitive intelligence helps BD&L teams get timely insights on promising assets, companies, technologies, and partnership opportunities before they become publicly obvious. Waiting for deal announcements to go public means you are entering the conversation after competitors have already identified, evaluated, pursued, and completed the deal.

While competitors or market shifts cannot be precisely predicted, a mature intelligence program can help BD&L teams anticipate potential moves by analyzing patterns and signals over time that reveal transaction strategies, such as repeated investments in a therapeutic area, partnerships around a specific technology, expansion into a particular market, or strategic gaps in a competitor’s portfolio.

For example, a competitor repeatedly partnering around a particular therapeutic area, expanding its scientific capabilities, hiring relevant leadership, and leaving a visible gap in its late-stage pipeline may indicate where future business-development activity could concentrate.

That said, recognizing patterns in transaction strategy becomes easier when your pharma M&CI platform provides historical data with a long enough context window to connect these signals over time. 

With Contify, you can access historical data, helping BD&L teams connect years of transaction, pipeline, scientific, and strategic signals to anticipate where competitors are likely to place their next bets.

This enables BD&L teams to:

• Scout undervalued assets before they attract competing bids
• Validate a target’s competitive position during diligence
• Benchmark deal terms against comparable transactions

Key market and competitive signals to monitor:

• Pipeline gaps and portfolio white spaces
• Emerging biotech companies and assets
• Licensing and partnership activity
• M&A history and transaction patterns
• Funding and investment activity
• Patent and scientific momentum
• Clinical progress of potential assets
• Therapeutic-area expansion
• Leadership commentary and strategic priorities
• Geographic expansion and hiring patterns

2. Portfolio & Pipeline Planning: Continuously test whether portfolio assumptions still hold

Offering forward-looking insights for pipeline and portfolio is standard for any M&CI platform. The National Institutes of Health reveals that 90% of drug development fails, where poor planning, changing market needs, or lack of commercial viability play a significant role. An M&CI program helps teams prioritize R&D efforts, identify potential risks early, and allocate resources to avoid commercial risks.

These insights can help teams understand which assets to invest in, what to deprioritize, and where to expand for new indications.

For instance, if you are starting the development of an asset because it shows a strong commercial opportunity, chances are that a competitor may show up with an advanced therapy, the standard of care may change, a new regulation may emerge, or the preference or population of the targeted patients may change. A reliable pharma market intelligence program connects these signals over time, helping portfolio teams:

• reassess the asset’s strategic value, 
• prioritize investment, 
• reconsider development plans, 
• or identify opportunities to differentiate the asset strategy without delay. 

Key market and competitive signals to monitor:

• Competitor pipeline composition and phase
• New pipeline entrants
• Pipeline discontinuations
• Indication expansions
• Development velocity
• Mechanism-of-action and modality trends
• Competitive density by indication
• Clinical differentiation
• Regulatory milestones
• Licensing and partnership activity
• Patent and exclusivity timelines
• Emerging standards of care

3. Clinical Development & R&D Strategy: Learn systematically from competing development programs

Clinical development and R&D teams use M&CI platforms to not only stay updated about competitors’ trial stages, but also understand how they are designing each stage behind the trials. This consists of monitoring comparator arms, patient inclusion and exclusion criteria, endpoints, protocol changes, and other trial design decisions.

For example, if competitors shift from surrogate endpoints to harder clinical outcomes, this could be a sign that regulatory standards or the standard of evidence in that indication are changing. Detecting this shift early allows clinical trial teams to reassess their own trial design, endpoints, or development strategy.

This helps clinical development and R&D teams to:

• Spot early changes in clinical and regulatory exceptions.
• Benchmark your own development strategy against your competitors and market standards.
• Bring timely adjustments to trial design and research priorities.
• Improve chances of clinical success.

Key market and competitive signals to monitor:

• Clinical trial registries
• Competitor trial protocols and updates
• Scientific publications
• Medical conferences and abstracts
• Regulatory filings and guidance
• Clinical trial results
• KOL commentary
• Drug labels and safety updates
• Patent filings
• Competitor pipeline updates

4. Regulatory Affairs: Turn regulatory developments into precedent and strategic context

Regulatory intelligence in pharma helps to monitor approvals, guidelines, safety notices, and agency announcements. Having said that, understanding what these developments mean for comparable assets provides greater value. An M&CI program helps pharma teams to know which competitors are facing safety-related label restrictions, delays in the review process, and receiving approvals for a narrower patient population. With these insights, teams can assess potential regulatory risks, benchmark their assets against comparable products, and make timely adjustments to their development and regulatory strategies.

Especially when you operate across borders, pharma regulatory intelligence becomes very crucial to stay aware of the evolving policies of that region, so that you can:

• Anticipate regulatory risks before they impact your assets
• Adapt development and filing strategies to evolving requirements
• Prepare for market entry based on region-specific approval and compliance requirements

Key market and competitive signals to monitor:

• Competitor submission timelines
• Approvals and rejections
• Regulatory designations
• Advisory committee activity
• Label language and label changes
• Safety communications
• Post-marketing commitments
• Regulatory guidelines and policy changes
• Filing and review timelines
• Country-specific regulatory developments
• Regulatory precedents for comparable assets
• Publicly disclosed interactions with regulators

5. Commercial and market access: understanding the market before launch

Commercial teams can utilize specific pharma intelligence such as competitor product positioning, healthcare provider (HCP) messaging, pricing and reimbursement activity, and more to identify how competitors are positioning their products to physicians, health systems, payers, and patients.

Pharmaceutical competitive intelligence also helps to sequence launches, anticipate payer objections before they even surface, and calibrate pricing against what the market has already accepted for comparable products.

Seeing these signals in isolation provides just updates; connecting these developments together tells you how your rivals are building their go-to-market strategy.

Key market and competitive signals to monitor:

• Launch timing and sequencing
• Geographic expansion
• Product positioning
• HCP messaging
• Pricing strategies
• Reimbursement decisions
• Formulary access
• HTA outcomes
• Payer positioning
• Patient-support programs
• KOL and medical-affairs activity
• Sales and commercial hiring
• Distribution partnerships
• Real-world evidence generation
• New indication launches
• Lifecycle-management strategies
• Competitor product-page and messaging changes

While all these teams make different decisions according to their use cases, their intelligence signals can overlap. This is why pharma intelligence teams need more than separate datasets for each team. Catering to the complexity of modern pharma intelligence use cases, a modern market and competitive intelligence platform must offer a shared intelligence layer that captures the same underlying signals at once, contextualizes them against the organization’s strategic priorities, and then distributes different implications to different teams.

Contify is a purpose-built pharma market and competitive intelligence tool that brings market monitoring, competitive intelligence, clinical and R&D intelligence, regulatory intelligence, and commercial intelligence together under one platform, instead of stitching together fragmented sources.

Gain 360-degree Pharma Intelligence Across the Drug Lifecycle

Market and competitive intelligence reports must evolve over time, as the drug moves to different stages of trials. In early stages, discovery and preclinical trials, pharma teams have more flexibility to make improvements and refocus on the direction. But as the asset progresses and moves to later stages, this flexibility starts to decline, as well as the cost of missing competitive, clinical, regulatory, or commercial signals increases exponentially.

That is why 360-degree intelligence should evolve with the asset’s journey and inform the stakeholders about critical external changes and what they can do about them before it is too late. The right M&CI platform connects signals from all stages and provides you with targeted intelligence that is focused on your specific strategic agenda across different trial stages.

Discovery and preclinical: detect early scientific and investment signals

Why intelligence is needed here: A competitor’s internal R&D decisions, such as which disease target to pursue, testing thousands of chemical compounds to know which one fits the target, and how much to invest before proof-of-concept, are decided a few years before it comes into public knowledge. By the time a mechanism shows up in a pipeline database, several companies have already committed capital to it.

What intelligence delivers: An M&CI platform helps to detect early warning signals to answer a broader intelligence question: Where is scientific and investment momentum beginning to concentrate?

Tracking emerging mechanisms of action, academic research, translational science, new biomarkers, university licensing, early biotech pipelines, venture funding, scientific collaborations, patent activity, and research hiring can be useful for catching the early strategic signals. A modern M&CI platform will connect these early signals to influence discovery strategy, external innovation, or licensing decisions.

Clinical development: understand how the competitive hypothesis is being tested

Why intelligence is needed here: In this stage, multiple companies are working on the same or related drugs and often compete on trial design. The endpoints, comparator arms, or patient populations that companies choose are a significant differentiator for their positioning. These choices are usually visible in clinical trial registries well before the results are announced.

What intelligence delivers: Clinical trial competitive intelligence helps companies benchmark their clinical design against their competitors, and then improve it through data-driven decisions. This includes monitoring endpoint selection, comparator arms, inclusion/exclusion criteria, protocol amendments, and recruitment timelines.

Regulatory review and approval: understand how the rules are being applied

Why intelligence is needed here: Non-alignment with drug regulatory bodies can lead to delays in approval, label restrictions, and additional discussions with regulators after submission.

What intelligence delivers: Regulatory intelligence in pharma helps to identify how the approval or submission process for similar drugs was in the past. An M&CI platform can get you these insights by tracking committee views, approval decisions, label changes, and regulatory approaches for similar assets. By analyzing these patterns, teams can make informed decisions about submission timing, filing strategy, and better regulatory planning.

Launch and commercialization: connect development history to market behavior

Why intelligence is needed here: A product’s poorly launched timing or wrong pricing strategies can affect the drug’s entry and performance in the market. This can impact the drug’s commercial success. It’s also important to analyze your competitors’ pricing, market access, value proposition, and messaging to outgrow them in the market.

What intelligence delivers: Tracking which markets competitors enter first, how payers respond to similar products, and how HCP sentiment changes after a competitor’s data release helps commercial teams adjust pricing, positioning, and launch sequencing before these decisions become too expensive to change.

Post-launch and loss of exclusivity: track how competitors extend or attack value

Why intelligence is needed here: At this stage, companies need to know how their drug is performing in the market. This constant surveillance is critical for quality and manufacturing consistency. Also, when the patent expires (usually after 10-20 years), the company’s revenue drops by almost 90%, which is specifically coming from that drug because of the patent cliff. After this, companies are more threatened by biosimilars and generics than by other branded drugs.

What intelligence delivers: Pharmaceutical Market and competitive intelligence platforms help pharma teams by tracking patent litigation, initiatives of biosimilar or generic filings, and how your competitors are using lifecycle management strategy via new formulations, new indications, and collaborations. By identifying these signals early, pharma companies can prepare for revenue erosion or, at the same time, build strategies for how they can extend the commercial life of their asset.

How Purpose-built AI Intelligence Platforms Are Changing Pharma Competitive Intelligence

Purpose-built AI workflows have transformed end-to-end pharma intelligence workflows, from data gathering and analysis to prediction and dissemination. The pharma industry often works with fragmented sources and a large volume of information, making it challenging to find signals early for making high-stakes decisions. Purpose-built AI intelligence workflows eliminate this complexity and time-consuming process by automating end-to-end workflows. 

AI-powered pharmaceutical market and competitive intelligence enables teams to:

• Compress the noise-to-signal ratio.
• Generate actionable insights on clinical trials, competitor activities, market trends, regulatory developments, and patent landscapes.
• Allow analysts to spend more time interpreting data rather than collecting and synthesizing it.
• Enable faster intelligence reports that reach stakeholders during decision windows, not after decisions are made. 

Traditionally, analysts have to search hundreds of fragmented sources to derive strategic signals. Especially with lean teams and quick reporting timelines, this process becomes humanly impossible. Modern M&CI platforms can continuously monitor millions of sources across different systems and capture signals relevant to your business context.

AI, when tailored to pharmaceutical intelligence workflows, can speed up the repetitive data synthesis process with the following capabilities:

• Relevance filtering: determining whether an update matches the intelligence scope.
• Entity resolution: distinguishing companies, products, assets, people, and other entities with similar names.
• Classification: applying therapeutic-area, disease, competitor, event, or strategic tags.
• Deduplication: combining repeated reporting of the same underlying event.
• Fact extraction: turning unstructured content into structured data points.
• Summarization: reducing lengthy documents to the information relevant to a particular question.
• Cross-signal synthesis: connecting multiple developments that relate to the same strategic theme.
• Distribution: routing the resulting intelligence to the appropriate stakeholder.

How Contify automated end-to-end pharma market and competitive workflows

Contify is a purpose-built pharma market and competitive intelligence platform that combines human-grade data integrity with proprietary agentic AI automation. It automatically translates a massive amount of unstructured information from competitors’ developments, clinical, patent, and regulatory updates into a hallucination-free, source-verified stream of insights, and then distributes role-specific, decision-ready intelligence to your entire R&D, clinical development, and GTM teams.

• Tailored Signal Mining: Contify allows highly targeted source monitoring across 1 million vetted external sources, which captures signals that are only aligned with your strategic objectives related to regions, products, themes, markets, competitors, therapeutic areas, and indications.

• Internal Data Integration: The platform also connects with your internal datasets such as CRM notes, knowledge base, clinical trial data, and proprietary research to contextualize insights that come from external sources, providing a complete view of the competitive and market landscape and helping teams understand external developments in the context of their own business.

• Automated, Multi-channel Dissemination: Contify ensures seamless intelligence dissemination by pushing role-specific, decision-ready insights directly to stakeholders in the format they want. Users get auto-updated dashboards that are configured to their strategic requirements. The platform also offers insight alerts for real-time updates and query-based answer generation for ad-hoc intelligence requests, supporting the dynamic needs of pharma use cases. Contify offers auto-curated, branded, and template-driven newsletters with performance analytics to ensure intelligence reaches and gets consumed enterprise-wide. With Contify, you can distribute insights to even non-platform users at no additional charge. 

• Asset-Level Signals Tracking: Pharma intelligence needs to track what is happening at the asset level, not just the company level. Contify’s Custom Fact Templates use AI to extract granular data specific to your business context from clinical, regulatory, patent, and scientific updates, turning unstructured information into structured, queryable facts. These facts automatically flow into Custom Insight Templates, so when a competitor advances a trial, reports new results, or receives a regulatory designation, your dashboards, newsletters, and battlecards update automatically. Contify also classifies intelligence according to your internal business context such as names of diseases, brands, or products, stripped of irrelevant information, and connected across related developments. 

• Multilingual Intelligence: Contify automatically translates and surfaces intelligence across 117+ languages, enabling cross-border teams to receive actionable insights in the language they prefer. In the pharma industry, specifically, it is often seen that critical developments often emerge first in local or regional sources before becoming globally visible. For instance, a drug may be approved in one country, under approval in another, or rejected in another–based on local regulatory policies that are often published in non-English languages.

Moreover, most pharma companies do not operate in a single national market; they operate across global markets. For example, your competitor may announce a partnership, launch plan, clinical development, or commercial strategy through its local subsidiary, local website, or regional trade publication. This is why Contify’s multilingual intelligence workflow ensures that international languages do not become a blind spot, allowing global pharma teams to discover, translate, and contextualize critical developments across markets and act on them regardless of where or in which language they originate.

Read the pharma competitive intelligence case study: Pharma company monitors competitors’ rare disease portfolio developments to identify opportunities and threats using Contify

Conclusion

With evolving drug developments, disease areas, and regulatory landscapes, the pharma industry is set to generate more signals than ever that can be leveraged to gain a competitive edge and drive better strategic decisions. The question is not about whether to leverage a market and competitive intelligence platform in pharma; it’s about which platform can reduce the distance between external changes and an informed strategic response. 

Nearly every modern market and competitive intelligence platform in pharma automates sourcing and validating insights. The differentiating factors are to connect signal sourcing with your strategic objectives and distribute them to the right stakeholders timely and effectively for decision-making. That requires shifting M&CI from a function supporting research to an intelligence operating system for the entire organization.